APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Long Acting Beta 2 Agonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long Acting Beta 2 Agonist Market Outlook and Growth Opportunities 2026

Report ID 174008730421 December 2025192 pages

Choose your research edition.

Industry ResearchLong Acting Beta 2 Agonist Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Long Acting Beta 2 Agonist Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Long Acting Beta 2 Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long Acting Beta 2 Agonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Long Acting Beta 2 Agonist Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Long Acting Beta 2 Agonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long Acting Beta 2 Agonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long Acting Beta 2 Agonist market include GSK, Teva, Novartis, Chiesi, AstraZeneca, Organon and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long Acting Beta 2 Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long Acting Beta 2 Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long Acting Beta 2 Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long Acting Beta 2 Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Long Acting Beta 2 Agonist Segment by Company

GSK

Teva

Novartis

Chiesi

AstraZeneca

Organon

Boehringer Ingelheim

Long Acting Beta 2 Agonist Segment by Type

Serevent

Foradil

Other

Long Acting Beta 2 Agonist Segment by Application

COPD

Asthma

Other

Long Acting Beta 2 Agonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long Acting Beta 2 Agonist status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Long Acting Beta 2 Agonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long Acting Beta 2 Agonist significant trends, drivers, influence factors in global and regions.

6. To analyze Long Acting Beta 2 Agonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long Acting Beta 2 Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long Acting Beta 2 Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long Acting Beta 2 Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long Acting Beta 2 Agonist market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long Acting Beta 2 Agonist industry.

Chapter 3: Detailed analysis of Long Acting Beta 2 Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Long Acting Beta 2 Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Long Acting Beta 2 Agonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long Acting Beta 2 Agonist Industry Trends Table 2. Long Acting Beta 2 Agonist Industry Drivers Table 3. Long Acting Beta 2 Agonist Industry Opportunities and Challenges Table 4. Long Acting Beta 2 Agonist Industry Restraints Table 5. Global Long Acting Beta 2 Agonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long Acting Beta 2 Agonist Revenue Share by Company (2021-2026) Table 7. Global Long Acting Beta 2 Agonist Sales Volume by Company (k units) & (2021-2026) Table 8. Global Long Acting Beta 2 Agonist Sales Volume Share by Company (2021-2026) Table 9. Global Long Acting Beta 2 Agonist Average Price (US$/unit) of Company (2021-2026) Table 10. Global Long Acting Beta 2 Agonist Company Ranking, (2024-2026) & (USD Million) Table 11. Global Long Acting Beta 2 Agonist Key Company Manufacturing Base & Headquarters Table 12. Global Long Acting Beta 2 Agonist Company, Product Type & Application Table 13. Global Long Acting Beta 2 Agonist Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Long Acting Beta 2 Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Serevent Table 18. Significant Companies of Foradil Table 19. Significant Companies of Other Table 20. Global Long Acting Beta 2 Agonist Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Long Acting Beta 2 Agonist Sales Volume by Type (2021-2026) & (k units) Table 22. Global Long Acting Beta 2 Agonist Sales Volume by Type (2027-2032) & (k units) Table 23. Global Long Acting Beta 2 Agonist Sales Volume Share by Type (2021-2026) Table 24. Global Long Acting Beta 2 Agonist Sales Volume Share by Type (2027-2032) Table 25. Global Long Acting Beta 2 Agonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Long Acting Beta 2 Agonist Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Long Acting Beta 2 Agonist Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Long Acting Beta 2 Agonist Sales Value Share by Type (2021-2026) Table 29. Global Long Acting Beta 2 Agonist Sales Value Share by Type (2027-2032) Table 30. Significant Companies of COPD Table 31. Significant Companies of Asthma Table 32. Significant Companies of Other Table 33. Global Long Acting Beta 2 Agonist Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Long Acting Beta 2 Agonist Sales Volume by Application (2021-2026) & (k units) Table 35. Global Long Acting Beta 2 Agonist Sales Volume by Application (2027-2032) & (k units) Table 36. Global Long Acting Beta 2 Agonist Sales Volume Share by Application (2021-2026) Table 37. Global Long Acting Beta 2 Agonist Sales Volume Share by Application (2027-2032) Table 38. Global Long Acting Beta 2 Agonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Long Acting Beta 2 Agonist Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Long Acting Beta 2 Agonist Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Long Acting Beta 2 Agonist Sales Value Share by Application (2021-2026) Table 42. Global Long Acting Beta 2 Agonist Sales Value Share by Application (2027-2032) Table 43. Global Long Acting Beta 2 Agonist Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Long Acting Beta 2 Agonist Sales by Region (2021-2026) & (k units) Table 45. Global Long Acting Beta 2 Agonist Sales Market Share by Region (2021-2026) Table 46. Global Long Acting Beta 2 Agonist Sales by Region (2027-2032) & (k units) Table 47. Global Long Acting Beta 2 Agonist Sales Market Share by Region (2027-2032) Table 48. Global Long Acting Beta 2 Agonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Long Acting Beta 2 Agonist Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Long Acting Beta 2 Agonist Sales Value Share by Region (2021-2026) Table 51. Global Long Acting Beta 2 Agonist Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Long Acting Beta 2 Agonist Sales Value Share by Region (2027-2032) Table 53. Global Long Acting Beta 2 Agonist Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Long Acting Beta 2 Agonist Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Long Acting Beta 2 Agonist Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Long Acting Beta 2 Agonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 58. Global Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2026) Table 59. Global Long Acting Beta 2 Agonist Sales by Country (2027-2032) & (k units) Table 60. Global Long Acting Beta 2 Agonist Sales Market Share by Country (2027-2032) Table 61. Global Long Acting Beta 2 Agonist Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Long Acting Beta 2 Agonist Sales Value Market Share by Country (2021-2026) Table 63. Global Long Acting Beta 2 Agonist Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Long Acting Beta 2 Agonist Sales Value Market Share by Country (2027-2032) Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. GSK Long Acting Beta 2 Agonist Product Portfolio Table 69. GSK Recent Development Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Teva Long Acting Beta 2 Agonist Product Portfolio Table 74. Teva Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Novartis Long Acting Beta 2 Agonist Product Portfolio Table 79. Novartis Recent Development Table 80. Chiesi Company Information Table 81. Chiesi Business Overview Table 82. Chiesi Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Chiesi Long Acting Beta 2 Agonist Product Portfolio Table 84. Chiesi Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. AstraZeneca Long Acting Beta 2 Agonist Product Portfolio Table 89. AstraZeneca Recent Development Table 90. Organon Company Information Table 91. Organon Business Overview Table 92. Organon Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Organon Long Acting Beta 2 Agonist Product Portfolio Table 94. Organon Recent Development Table 95. Boehringer Ingelheim Company Information Table 96. Boehringer Ingelheim Business Overview Table 97. Boehringer Ingelheim Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Boehringer Ingelheim Long Acting Beta 2 Agonist Product Portfolio Table 99. Boehringer Ingelheim Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Long Acting Beta 2 Agonist Distributors List Table 103. Long Acting Beta 2 Agonist Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Long Acting Beta 2 Agonist Product Image Figure 2. Global Long Acting Beta 2 Agonist Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long Acting Beta 2 Agonist Sales Value (2021-2032) & (US$ Million) Figure 4. Global Long Acting Beta 2 Agonist Sales (2021-2032) & (k units) Figure 5. Global Long Acting Beta 2 Agonist Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Long Acting Beta 2 Agonist Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Serevent Image Figure 10. Foradil Image Figure 11. Other Image Figure 12. Global Long Acting Beta 2 Agonist Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Long Acting Beta 2 Agonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Long Acting Beta 2 Agonist Sales Volume Share by Type (2021-2032) Figure 15. Global Long Acting Beta 2 Agonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Long Acting Beta 2 Agonist Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Long Acting Beta 2 Agonist Sales Value Share by Type (2021-2032) Figure 18. COPD Image Figure 19. Asthma Image Figure 20. Other Image Figure 21. Global Long Acting Beta 2 Agonist Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Long Acting Beta 2 Agonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Long Acting Beta 2 Agonist Sales Volume Share by Application (2021-2032) Figure 24. Global Long Acting Beta 2 Agonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Long Acting Beta 2 Agonist Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Long Acting Beta 2 Agonist Sales Value Share by Application (2021-2032) Figure 27. Global Long Acting Beta 2 Agonist Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Long Acting Beta 2 Agonist Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Long Acting Beta 2 Agonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Long Acting Beta 2 Agonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Long Acting Beta 2 Agonist Sales Value (2021-2032) & (US$ Million) Figure 32. North America Long Acting Beta 2 Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Long Acting Beta 2 Agonist Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Long Acting Beta 2 Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Long Acting Beta 2 Agonist Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Long Acting Beta 2 Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Long Acting Beta 2 Agonist Sales Value (2021-2032) & (US$ Million) Figure 38. South America Long Acting Beta 2 Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Long Acting Beta 2 Agonist Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Long Acting Beta 2 Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Long Acting Beta 2 Agonist Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Long Acting Beta 2 Agonist Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Serevent
  • Foradil
  • Other
Applications
  • COPD
  • Asthma
  • Other
Companies covered
  • GSK
  • Teva
  • Novartis
  • Chiesi
  • AstraZeneca
  • Organon
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long Acting Beta 2 Agonist Sales Value (2021-2032)
  4. 1.2.2 Global Long Acting Beta 2 Agonist Sales Volume (2021-2032)
  5. 1.2.3 Global Long Acting Beta 2 Agonist Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Long Acting Beta 2 Agonist Market Dynamics
  1. 2.1 Long Acting Beta 2 Agonist Industry Trends
  2. 2.2 Long Acting Beta 2 Agonist Industry Drivers
  3. 2.3 Long Acting Beta 2 Agonist Industry Opportunities and Challenges
  4. 2.4 Long Acting Beta 2 Agonist Industry Restraints
3 Long Acting Beta 2 Agonist Market by Company
  1. 3.1 Global Long Acting Beta 2 Agonist Company Revenue Ranking in 2025
  2. 3.2 Global Long Acting Beta 2 Agonist Revenue by Company (2021-2026)
  3. 3.3 Global Long Acting Beta 2 Agonist Sales Volume by Company (2021-2026)
  4. 3.4 Global Long Acting Beta 2 Agonist Average Price by Company (2021-2026)
  5. 3.5 Global Long Acting Beta 2 Agonist Company Ranking (2024-2026)
  6. 3.6 Global Long Acting Beta 2 Agonist Company Manufacturing Base and Headquarters
  7. 3.7 Global Long Acting Beta 2 Agonist Company Product Type and Application
  8. 3.8 Global Long Acting Beta 2 Agonist Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Long Acting Beta 2 Agonist Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Long Acting Beta 2 Agonist Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Long Acting Beta 2 Agonist Market by Type
  1. 4.1 Long Acting Beta 2 Agonist Type Introduction
  2. 4.1.1 Serevent
  3. 4.1.2 Foradil
  4. 4.1.3 Other
  5. 4.2 Global Long Acting Beta 2 Agonist Sales Volume by Type
  6. 4.2.1 Global Long Acting Beta 2 Agonist Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long Acting Beta 2 Agonist Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Long Acting Beta 2 Agonist Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Long Acting Beta 2 Agonist Sales Value by Type
  10. 4.3.1 Global Long Acting Beta 2 Agonist Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Long Acting Beta 2 Agonist Sales Value by Type (2021-2032)
  12. 4.3.3 Global Long Acting Beta 2 Agonist Sales Value Share by Type (2021-2032)
5 Long Acting Beta 2 Agonist Market by Application
  1. 5.1 Long Acting Beta 2 Agonist Application Introduction
  2. 5.1.1 COPD
  3. 5.1.2 Asthma
  4. 5.1.3 Other
  5. 5.2 Global Long Acting Beta 2 Agonist Sales Volume by Application
  6. 5.2.1 Global Long Acting Beta 2 Agonist Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long Acting Beta 2 Agonist Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Long Acting Beta 2 Agonist Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Long Acting Beta 2 Agonist Sales Value by Application
  10. 5.3.1 Global Long Acting Beta 2 Agonist Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Long Acting Beta 2 Agonist Sales Value by Application (2021-2032)
  12. 5.3.3 Global Long Acting Beta 2 Agonist Sales Value Share by Application (2021-2032)
6 Long Acting Beta 2 Agonist Regional Sales and Value Analysis
  1. 6.1 Global Long Acting Beta 2 Agonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long Acting Beta 2 Agonist Sales by Region (2021-2032)
  3. 6.2.1 Global Long Acting Beta 2 Agonist Sales by Region: 2021-2026
  4. 6.2.2 Global Long Acting Beta 2 Agonist Sales by Region (2027-2032)
  5. 6.3 Global Long Acting Beta 2 Agonist Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Long Acting Beta 2 Agonist Sales Value by Region (2021-2032)
  7. 6.4.1 Global Long Acting Beta 2 Agonist Sales Value by Region: 2021-2026
  8. 6.4.2 Global Long Acting Beta 2 Agonist Sales Value by Region (2027-2032)
  9. 6.5 Global Long Acting Beta 2 Agonist Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Long Acting Beta 2 Agonist Sales Value (2021-2032)
  12. 6.6.2 North America Long Acting Beta 2 Agonist Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Long Acting Beta 2 Agonist Sales Value (2021-2032)
  15. 6.7.2 Europe Long Acting Beta 2 Agonist Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Long Acting Beta 2 Agonist Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Long Acting Beta 2 Agonist Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Long Acting Beta 2 Agonist Sales Value (2021-2032)
  21. 6.9.2 South America Long Acting Beta 2 Agonist Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Long Acting Beta 2 Agonist Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Long Acting Beta 2 Agonist Sales Value Share by Country, 2025 VS 2032
7 Long Acting Beta 2 Agonist Country-level Sales and Value Analysis
  1. 7.1 Global Long Acting Beta 2 Agonist Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long Acting Beta 2 Agonist Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Long Acting Beta 2 Agonist Sales by Country (2021-2032)
  4. 7.3.1 Global Long Acting Beta 2 Agonist Sales by Country (2021-2026)
  5. 7.3.2 Global Long Acting Beta 2 Agonist Sales by Country (2027-2032)
  6. 7.4 Global Long Acting Beta 2 Agonist Sales Value by Country (2021-2032)
  7. 7.4.1 Global Long Acting Beta 2 Agonist Sales Value by Country (2021-2026)
  8. 7.4.2 Global Long Acting Beta 2 Agonist Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Long Acting Beta 2 Agonist Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Long Acting Beta 2 Agonist Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Long Acting Beta 2 Agonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Long Acting Beta 2 Agonist Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Long Acting Beta 2 Agonist Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Long Acting Beta 2 Agonist Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Long Acting Beta 2 Agonist Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Long Acting Beta 2 Agonist Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Long Acting Beta 2 Agonist Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Chiesi
  20. 8.4.1 Chiesi Company Information
  21. 8.4.2 Chiesi Business Overview
  22. 8.4.3 Chiesi Long Acting Beta 2 Agonist Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chiesi Long Acting Beta 2 Agonist Product Portfolio
  24. 8.4.5 Chiesi Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Long Acting Beta 2 Agonist Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Long Acting Beta 2 Agonist Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Organon
  32. 8.6.1 Organon Company Information
  33. 8.6.2 Organon Business Overview
  34. 8.6.3 Organon Long Acting Beta 2 Agonist Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Organon Long Acting Beta 2 Agonist Product Portfolio
  36. 8.6.5 Organon Recent Developments
  37. 8.7 Boehringer Ingelheim
  38. 8.7.1 Boehringer Ingelheim Company Information
  39. 8.7.2 Boehringer Ingelheim Business Overview
  40. 8.7.3 Boehringer Ingelheim Long Acting Beta 2 Agonist Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim Long Acting Beta 2 Agonist Product Portfolio
  42. 8.7.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long Acting Beta 2 Agonist Value Chain Analysis
  2. 9.1.1 Long Acting Beta 2 Agonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long Acting Beta 2 Agonist Sales Mode & Process
  6. 9.2 Long Acting Beta 2 Agonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long Acting Beta 2 Agonist Distributors
  9. 9.2.3 Long Acting Beta 2 Agonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst